Review



rabbit polyclonal anti adgrg6 antibody  (Proteintech)


Bioz Verified Symbol Proteintech is a verified supplier  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 93

    Structured Review

    Proteintech rabbit polyclonal anti adgrg6 antibody
    Expression levels of <t>ADGRG6</t> mRNA in PAAD and clinical subgroups (GEPIA and UALCAN). ( A ) Comparison of ADGRG6 mRNA expression between PAAD tissues ( n = 179) and normal tissues ( n = 171) from the GEPIA database (TCGA + GTEx). ( B – I ) UALCAN-based subgroup analysis of ADGRG6 expression levels in PAAD samples stratified by sex ( B ), pancreatitis status ( C ), age ( D ), drinking habits ( E ), diabetes status ( F ), tumor grade ( G ), lymph node metastasis ( H ), and TP53 mutation status ( I ). The “normal” group in UALCAN ( n = 4) includes adjacent non-tumor tissues, without subgroup annotations. The comparison to the “normal” group in the UALCAN analysis should be interpreted with caution due to the small size of the normal cohort ( n = 4). “Drinking status” data is incomplete (missing in 80 samples), and comparisons among subgroups should be interpreted cautiously. Subtype descriptions of “Tumor Grade”: Grade 1-Well differentiated (low grade), Grade 2-Moderately differentiated (intermediate grade), Grade 3-Poorly differentiated (high grade), Grade 4-Undifferentiated (high grade). Pathologic descriptions of “Nodal Metastasis Status”: N0-No regional lymph node metastasis, N1-Metastases in 1 to 3 axillary lymph nodes. Data are presented as Mean ± SD. Statistical analysis was performed using Student’s t -test for two-group comparisons and one-way ANOVA followed by Bonferroni’s post hoc test. “*” indicates comparison with the control group; “#” indicates significance between experimental groups (* p < 0.05, ** p < 0.01, *** p < 0.001; # p < 0.05, ## p < 0.01).
    Rabbit Polyclonal Anti Adgrg6 Antibody, supplied by Proteintech, used in various techniques. Bioz Stars score: 93/100, based on 4 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/rabbit+polyclonal+anti+adgrg6+antibody/GPR126+Antibody/pmc12731683-69-10-15
    Average 93 stars, based on 4 article reviews
    rabbit polyclonal anti adgrg6 antibody - by Bioz Stars, 2026-09
    93/100 stars

    Images

    1) Product Images from "ADGRG6 Promotes Pancreatic Adenocarcinoma Progression Through the NF-κB/STAT6 Axis and Modulation of the Tumor Immune Microenvironment"

    Article Title: ADGRG6 Promotes Pancreatic Adenocarcinoma Progression Through the NF-κB/STAT6 Axis and Modulation of the Tumor Immune Microenvironment

    Journal: Current Issues in Molecular Biology

    doi: 10.3390/cimb47120991

    Expression levels of ADGRG6 mRNA in PAAD and clinical subgroups (GEPIA and UALCAN). ( A ) Comparison of ADGRG6 mRNA expression between PAAD tissues ( n = 179) and normal tissues ( n = 171) from the GEPIA database (TCGA + GTEx). ( B – I ) UALCAN-based subgroup analysis of ADGRG6 expression levels in PAAD samples stratified by sex ( B ), pancreatitis status ( C ), age ( D ), drinking habits ( E ), diabetes status ( F ), tumor grade ( G ), lymph node metastasis ( H ), and TP53 mutation status ( I ). The “normal” group in UALCAN ( n = 4) includes adjacent non-tumor tissues, without subgroup annotations. The comparison to the “normal” group in the UALCAN analysis should be interpreted with caution due to the small size of the normal cohort ( n = 4). “Drinking status” data is incomplete (missing in 80 samples), and comparisons among subgroups should be interpreted cautiously. Subtype descriptions of “Tumor Grade”: Grade 1-Well differentiated (low grade), Grade 2-Moderately differentiated (intermediate grade), Grade 3-Poorly differentiated (high grade), Grade 4-Undifferentiated (high grade). Pathologic descriptions of “Nodal Metastasis Status”: N0-No regional lymph node metastasis, N1-Metastases in 1 to 3 axillary lymph nodes. Data are presented as Mean ± SD. Statistical analysis was performed using Student’s t -test for two-group comparisons and one-way ANOVA followed by Bonferroni’s post hoc test. “*” indicates comparison with the control group; “#” indicates significance between experimental groups (* p < 0.05, ** p < 0.01, *** p < 0.001; # p < 0.05, ## p < 0.01).
    Figure Legend Snippet: Expression levels of ADGRG6 mRNA in PAAD and clinical subgroups (GEPIA and UALCAN). ( A ) Comparison of ADGRG6 mRNA expression between PAAD tissues ( n = 179) and normal tissues ( n = 171) from the GEPIA database (TCGA + GTEx). ( B – I ) UALCAN-based subgroup analysis of ADGRG6 expression levels in PAAD samples stratified by sex ( B ), pancreatitis status ( C ), age ( D ), drinking habits ( E ), diabetes status ( F ), tumor grade ( G ), lymph node metastasis ( H ), and TP53 mutation status ( I ). The “normal” group in UALCAN ( n = 4) includes adjacent non-tumor tissues, without subgroup annotations. The comparison to the “normal” group in the UALCAN analysis should be interpreted with caution due to the small size of the normal cohort ( n = 4). “Drinking status” data is incomplete (missing in 80 samples), and comparisons among subgroups should be interpreted cautiously. Subtype descriptions of “Tumor Grade”: Grade 1-Well differentiated (low grade), Grade 2-Moderately differentiated (intermediate grade), Grade 3-Poorly differentiated (high grade), Grade 4-Undifferentiated (high grade). Pathologic descriptions of “Nodal Metastasis Status”: N0-No regional lymph node metastasis, N1-Metastases in 1 to 3 axillary lymph nodes. Data are presented as Mean ± SD. Statistical analysis was performed using Student’s t -test for two-group comparisons and one-way ANOVA followed by Bonferroni’s post hoc test. “*” indicates comparison with the control group; “#” indicates significance between experimental groups (* p < 0.05, ** p < 0.01, *** p < 0.001; # p < 0.05, ## p < 0.01).

    Techniques Used: Expressing, Comparison, Mutagenesis, Control

    Protein expression of ADGRG6 in PAAD based on UALCAN and HPA databases. ( A ) Comparison of ADGRG6 protein expression between PAAD tissues ( n = 137) and normal pancreatic tissues ( n = 74) using the UALCAN database (CPTAC dataset). ( B – L ) Subgroup analyses of ADGRG6 protein expression stratified by sex ( B ), chromatin modifier alteration status ( C ), age ( D ), weight ( E ), tumor grade ( F ), tumor stage ( G ), MYC/MYCN alteration ( H ), SWI/SNF complex alteration ( I ), and activity status of the mTOR ( J ), Hippo ( K ), and RTK ( L ) signal pathways. Each subgroup was compared to normal tissues. The “others” group in ( C , H – L ) refers to patients without the specific mutation or alteration listed. ( M ) Representative IHC staining images from the HPA database showing ADGRG6 expression in normal pancreatic tissue and PAAD tissue. Scale Bar: 200 µm. Data are presented as Mean ± SD. Statistical analysis was performed using Student’s t -test for two-group comparisons and one-way ANOVA followed by Bonferroni’s post hoc test. “*” indicates comparison with the control group; “#” indicates significance between experimental groups (* p < 0.05, *** p < 0.001; # p < 0.05).
    Figure Legend Snippet: Protein expression of ADGRG6 in PAAD based on UALCAN and HPA databases. ( A ) Comparison of ADGRG6 protein expression between PAAD tissues ( n = 137) and normal pancreatic tissues ( n = 74) using the UALCAN database (CPTAC dataset). ( B – L ) Subgroup analyses of ADGRG6 protein expression stratified by sex ( B ), chromatin modifier alteration status ( C ), age ( D ), weight ( E ), tumor grade ( F ), tumor stage ( G ), MYC/MYCN alteration ( H ), SWI/SNF complex alteration ( I ), and activity status of the mTOR ( J ), Hippo ( K ), and RTK ( L ) signal pathways. Each subgroup was compared to normal tissues. The “others” group in ( C , H – L ) refers to patients without the specific mutation or alteration listed. ( M ) Representative IHC staining images from the HPA database showing ADGRG6 expression in normal pancreatic tissue and PAAD tissue. Scale Bar: 200 µm. Data are presented as Mean ± SD. Statistical analysis was performed using Student’s t -test for two-group comparisons and one-way ANOVA followed by Bonferroni’s post hoc test. “*” indicates comparison with the control group; “#” indicates significance between experimental groups (* p < 0.05, *** p < 0.001; # p < 0.05).

    Techniques Used: Expressing, Comparison, Activity Assay, Mutagenesis, Immunohistochemistry, Control

    Prognostic value of ADGRG6 expression in PAAD. ( A ) Kaplan–Meier survival curves showing OS relative to ADGRG6 expression. ( B – I ) Subgroup OS analyses, including ( B , C ) gender, ( D , E ) stage 1–2, ( F ) T2 (tumor size > 2 cm but ≤4 cm), ( G ) T3 (tumor size > 4 cm), ( H ) N0 (no regional lymph node metastasis), and ( I ) M0 (no distant metastasis).
    Figure Legend Snippet: Prognostic value of ADGRG6 expression in PAAD. ( A ) Kaplan–Meier survival curves showing OS relative to ADGRG6 expression. ( B – I ) Subgroup OS analyses, including ( B , C ) gender, ( D , E ) stage 1–2, ( F ) T2 (tumor size > 2 cm but ≤4 cm), ( G ) T3 (tumor size > 4 cm), ( H ) N0 (no regional lymph node metastasis), and ( I ) M0 (no distant metastasis).

    Techniques Used: Expressing

    Single-cell analysis of ADGRG6 in the TME. ( A ) TISCH database analysis of ADGRG6 expression across different cell types in the TME. ( B , C ) The distribution of ADGRG6 expression in various immune and stromal cell types in the PAAD_CRA001160 and PAAD_GSE154778 datasets. The left panels ( B , C ) depict the Uniform manifold approximation and projection (UMAP) of single-cell transcriptome data with cell typing (major lineages) in the two datasets. The right panels ( B , C ) show the expression of the ADGRG6 gene in different cell types (major lineages) within the two datasets.
    Figure Legend Snippet: Single-cell analysis of ADGRG6 in the TME. ( A ) TISCH database analysis of ADGRG6 expression across different cell types in the TME. ( B , C ) The distribution of ADGRG6 expression in various immune and stromal cell types in the PAAD_CRA001160 and PAAD_GSE154778 datasets. The left panels ( B , C ) depict the Uniform manifold approximation and projection (UMAP) of single-cell transcriptome data with cell typing (major lineages) in the two datasets. The right panels ( B , C ) show the expression of the ADGRG6 gene in different cell types (major lineages) within the two datasets.

    Techniques Used: Single-cell Analysis, Expressing

    ADGRG6 silencing suppresses PAAD cell proliferation, migration, and invasion in vitro. ( A ) IHC staining of ADGRG6 in PAAD tissues based on tissue microarray analysis, showing higher expression in advanced TNM stages. Scale Bar: 200 µm. ( B ) ADGRG6 mRNA levels in AsPC-1 and BxPC-3 post si- ADGRG6 . ( C ) Cell proliferation of si- ADGRG6 -transfected AsPC-1 and BxPC-3 measured by CCK-8 assay. ( D ) Wound-healing assay demonstrating reduced migration capacity in si- ADGRG6 -transfected AsPC-1 and BxPC-3 cells. Scale Bar: 50 µm. ( E ) Transwell invasion assays (200×) confirming decreased invasive ability post-knockdown. Scale Bar: 50 µm. ( F ) 3D spheroid culture assays demonstrating impaired spheroid growth in si- ADGRG6 cells, quantified by spheroid diameters across 21 days (4×). Scale Bar: 200 µm. Data are presented as Mean ± SD. Statistical analysis was performed using Student’s t -test for two-group comparisons and one-way ANOVA followed by Bonferroni’s post hoc test. “*” indicates comparison with the control group; “#” indicates significance between experimental groups (** p < 0.01, *** p < 0.001; # p < 0.05).
    Figure Legend Snippet: ADGRG6 silencing suppresses PAAD cell proliferation, migration, and invasion in vitro. ( A ) IHC staining of ADGRG6 in PAAD tissues based on tissue microarray analysis, showing higher expression in advanced TNM stages. Scale Bar: 200 µm. ( B ) ADGRG6 mRNA levels in AsPC-1 and BxPC-3 post si- ADGRG6 . ( C ) Cell proliferation of si- ADGRG6 -transfected AsPC-1 and BxPC-3 measured by CCK-8 assay. ( D ) Wound-healing assay demonstrating reduced migration capacity in si- ADGRG6 -transfected AsPC-1 and BxPC-3 cells. Scale Bar: 50 µm. ( E ) Transwell invasion assays (200×) confirming decreased invasive ability post-knockdown. Scale Bar: 50 µm. ( F ) 3D spheroid culture assays demonstrating impaired spheroid growth in si- ADGRG6 cells, quantified by spheroid diameters across 21 days (4×). Scale Bar: 200 µm. Data are presented as Mean ± SD. Statistical analysis was performed using Student’s t -test for two-group comparisons and one-way ANOVA followed by Bonferroni’s post hoc test. “*” indicates comparison with the control group; “#” indicates significance between experimental groups (** p < 0.01, *** p < 0.001; # p < 0.05).

    Techniques Used: Migration, In Vitro, Immunohistochemistry, Microarray, Expressing, Transfection, CCK-8 Assay, Wound Healing Assay, Knockdown, Comparison, Control

    In vivo evidence of ADGRG6 oncogenic function in zebrafish and murine xenograft models. ( A ) Representative fluorescence microscopy images of zebrafish xenografts injected with CM-DiI-labeled AsPC-1 cells (si-NC vs. si- ADGRG6 ) at 48 h post-injection (hpi), showing reduced tumor fluorescence area in si- ADGRG6 xenografts. Scale Bar: 300 µm. ( B ) Migration distance of tumor cells in zebrafish xenografts at 24 hpi, significantly reduced upon ADGRG6 knockdown. Fluorescence (red) resulting from CM-Dil labeling was used to monitor the behavior of the cells in the zebrafish model. ( C ) Relative ADGRG6 mRNA and ( D ) protein levels in AsPC-1 cells transfected with siRNA. ( E ) Representative images of mice in vivo tumorigenesis assay. ( F ) Representative images of excised tumors from the tumor-bearing mice. ( G ) Body weight of mice across groups was measured every three days for each mouse and the growth curve was plotted ( n = 6). ( H ) Comparison of the tumor weight ( n = 6). Data are presented as Mean ± SD. Statistical analysis was performed using Student’s t -test for two-group comparisons and one-way ANOVA followed by Bonferroni’s post hoc test. * p < 0.05, *** p < 0.001.
    Figure Legend Snippet: In vivo evidence of ADGRG6 oncogenic function in zebrafish and murine xenograft models. ( A ) Representative fluorescence microscopy images of zebrafish xenografts injected with CM-DiI-labeled AsPC-1 cells (si-NC vs. si- ADGRG6 ) at 48 h post-injection (hpi), showing reduced tumor fluorescence area in si- ADGRG6 xenografts. Scale Bar: 300 µm. ( B ) Migration distance of tumor cells in zebrafish xenografts at 24 hpi, significantly reduced upon ADGRG6 knockdown. Fluorescence (red) resulting from CM-Dil labeling was used to monitor the behavior of the cells in the zebrafish model. ( C ) Relative ADGRG6 mRNA and ( D ) protein levels in AsPC-1 cells transfected with siRNA. ( E ) Representative images of mice in vivo tumorigenesis assay. ( F ) Representative images of excised tumors from the tumor-bearing mice. ( G ) Body weight of mice across groups was measured every three days for each mouse and the growth curve was plotted ( n = 6). ( H ) Comparison of the tumor weight ( n = 6). Data are presented as Mean ± SD. Statistical analysis was performed using Student’s t -test for two-group comparisons and one-way ANOVA followed by Bonferroni’s post hoc test. * p < 0.05, *** p < 0.001.

    Techniques Used: In Vivo, Fluorescence, Microscopy, Injection, Labeling, Migration, Knockdown, Transfection, Comparison

    Regulatory Role of ADGRG6 in the NF-κB→STAT6→GATA3 Signaling Axis. ( A ) KEGG pathway analysis of the gene set co-expressed with ADGRG6 using the LinkInterpreter module; ( B – E ) Pearson correlation analysis between ADGRG6 and key genes of the signaling axis ( NFKB1 , RELA , STAT6 , and GATA3 ) in 178 clinical samples. Values represent Pearson correlation coefficients and corresponding p -values, n = 178; ( F , G ) Relative expression levels of STAT6 and GATA3 genes in the signaling axis in AsPC-1 and BxPC-3 cells after ADGRG6 knockdown detected by RT-qPCR. Data are presented as mean ± standard deviation; ( H , I ) Secretion levels of secretory cytokines IL-6 and IL-8 in AsPC-1 and BxPC-3 cells detected by ELISA; ( J ) Expression and activity of key proteins in the signaling axis after ADGRG6 knockdown detected by Western blot, *** p < 0.001.
    Figure Legend Snippet: Regulatory Role of ADGRG6 in the NF-κB→STAT6→GATA3 Signaling Axis. ( A ) KEGG pathway analysis of the gene set co-expressed with ADGRG6 using the LinkInterpreter module; ( B – E ) Pearson correlation analysis between ADGRG6 and key genes of the signaling axis ( NFKB1 , RELA , STAT6 , and GATA3 ) in 178 clinical samples. Values represent Pearson correlation coefficients and corresponding p -values, n = 178; ( F , G ) Relative expression levels of STAT6 and GATA3 genes in the signaling axis in AsPC-1 and BxPC-3 cells after ADGRG6 knockdown detected by RT-qPCR. Data are presented as mean ± standard deviation; ( H , I ) Secretion levels of secretory cytokines IL-6 and IL-8 in AsPC-1 and BxPC-3 cells detected by ELISA; ( J ) Expression and activity of key proteins in the signaling axis after ADGRG6 knockdown detected by Western blot, *** p < 0.001.

    Techniques Used: Expressing, Knockdown, Quantitative RT-PCR, Standard Deviation, Enzyme-linked Immunosorbent Assay, Activity Assay, Western Blot

    Related Articles

    Incubation:

    Article Title: ADGRG6 Promotes Pancreatic Adenocarcinoma Progression Through the NF-κB/STAT6 Axis and Modulation of the Tumor Immune Microenvironment
    Article Snippet: .. Sections were then incubated overnight at 4 °C with a rabbit polyclonal anti-ADGRG6 antibody (1:500; Proteintech, Rosemont, IL, USA, Cat. no. 17774-1-AP). ..



    Similar Products

    93
    Proteintech rabbit polyclonal anti adgrg6 antibody
    Expression levels of <t>ADGRG6</t> mRNA in PAAD and clinical subgroups (GEPIA and UALCAN). ( A ) Comparison of ADGRG6 mRNA expression between PAAD tissues ( n = 179) and normal tissues ( n = 171) from the GEPIA database (TCGA + GTEx). ( B – I ) UALCAN-based subgroup analysis of ADGRG6 expression levels in PAAD samples stratified by sex ( B ), pancreatitis status ( C ), age ( D ), drinking habits ( E ), diabetes status ( F ), tumor grade ( G ), lymph node metastasis ( H ), and TP53 mutation status ( I ). The “normal” group in UALCAN ( n = 4) includes adjacent non-tumor tissues, without subgroup annotations. The comparison to the “normal” group in the UALCAN analysis should be interpreted with caution due to the small size of the normal cohort ( n = 4). “Drinking status” data is incomplete (missing in 80 samples), and comparisons among subgroups should be interpreted cautiously. Subtype descriptions of “Tumor Grade”: Grade 1-Well differentiated (low grade), Grade 2-Moderately differentiated (intermediate grade), Grade 3-Poorly differentiated (high grade), Grade 4-Undifferentiated (high grade). Pathologic descriptions of “Nodal Metastasis Status”: N0-No regional lymph node metastasis, N1-Metastases in 1 to 3 axillary lymph nodes. Data are presented as Mean ± SD. Statistical analysis was performed using Student’s t -test for two-group comparisons and one-way ANOVA followed by Bonferroni’s post hoc test. “*” indicates comparison with the control group; “#” indicates significance between experimental groups (* p < 0.05, ** p < 0.01, *** p < 0.001; # p < 0.05, ## p < 0.01).
    Rabbit Polyclonal Anti Adgrg6 Antibody, supplied by Proteintech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/rabbit+polyclonal+anti+adgrg6+antibody/GPR126+Antibody/pmc12731683-69-10-15
    Average 93 stars, based on 1 article reviews
    rabbit polyclonal anti adgrg6 antibody - by Bioz Stars, 2026-09
    93/100 stars
      Buy from Supplier

    93
    OriGene anti adgrg6
    Expression levels of <t>ADGRG6</t> mRNA in PAAD and clinical subgroups (GEPIA and UALCAN). ( A ) Comparison of ADGRG6 mRNA expression between PAAD tissues ( n = 179) and normal tissues ( n = 171) from the GEPIA database (TCGA + GTEx). ( B – I ) UALCAN-based subgroup analysis of ADGRG6 expression levels in PAAD samples stratified by sex ( B ), pancreatitis status ( C ), age ( D ), drinking habits ( E ), diabetes status ( F ), tumor grade ( G ), lymph node metastasis ( H ), and TP53 mutation status ( I ). The “normal” group in UALCAN ( n = 4) includes adjacent non-tumor tissues, without subgroup annotations. The comparison to the “normal” group in the UALCAN analysis should be interpreted with caution due to the small size of the normal cohort ( n = 4). “Drinking status” data is incomplete (missing in 80 samples), and comparisons among subgroups should be interpreted cautiously. Subtype descriptions of “Tumor Grade”: Grade 1-Well differentiated (low grade), Grade 2-Moderately differentiated (intermediate grade), Grade 3-Poorly differentiated (high grade), Grade 4-Undifferentiated (high grade). Pathologic descriptions of “Nodal Metastasis Status”: N0-No regional lymph node metastasis, N1-Metastases in 1 to 3 axillary lymph nodes. Data are presented as Mean ± SD. Statistical analysis was performed using Student’s t -test for two-group comparisons and one-way ANOVA followed by Bonferroni’s post hoc test. “*” indicates comparison with the control group; “#” indicates significance between experimental groups (* p < 0.05, ** p < 0.01, *** p < 0.001; # p < 0.05, ## p < 0.01).
    Anti Adgrg6, supplied by OriGene, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/rabbit+polyclonal+anti+adgrg6+antibody/GPR126+(ADGRG6)+Rabbit+Polyclonal+Antibody/pm41265596-115-7-8
    Average 93 stars, based on 1 article reviews
    anti adgrg6 - by Bioz Stars, 2026-09
    93/100 stars
      Buy from Supplier

    91
    Cusabio adgrg6
    Expression levels of <t>ADGRG6</t> mRNA in PAAD and clinical subgroups (GEPIA and UALCAN). ( A ) Comparison of ADGRG6 mRNA expression between PAAD tissues ( n = 179) and normal tissues ( n = 171) from the GEPIA database (TCGA + GTEx). ( B – I ) UALCAN-based subgroup analysis of ADGRG6 expression levels in PAAD samples stratified by sex ( B ), pancreatitis status ( C ), age ( D ), drinking habits ( E ), diabetes status ( F ), tumor grade ( G ), lymph node metastasis ( H ), and TP53 mutation status ( I ). The “normal” group in UALCAN ( n = 4) includes adjacent non-tumor tissues, without subgroup annotations. The comparison to the “normal” group in the UALCAN analysis should be interpreted with caution due to the small size of the normal cohort ( n = 4). “Drinking status” data is incomplete (missing in 80 samples), and comparisons among subgroups should be interpreted cautiously. Subtype descriptions of “Tumor Grade”: Grade 1-Well differentiated (low grade), Grade 2-Moderately differentiated (intermediate grade), Grade 3-Poorly differentiated (high grade), Grade 4-Undifferentiated (high grade). Pathologic descriptions of “Nodal Metastasis Status”: N0-No regional lymph node metastasis, N1-Metastases in 1 to 3 axillary lymph nodes. Data are presented as Mean ± SD. Statistical analysis was performed using Student’s t -test for two-group comparisons and one-way ANOVA followed by Bonferroni’s post hoc test. “*” indicates comparison with the control group; “#” indicates significance between experimental groups (* p < 0.05, ** p < 0.01, *** p < 0.001; # p < 0.05, ## p < 0.01).
    Adgrg6, supplied by Cusabio, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/rabbit+polyclonal+anti+adgrg6+antibody/Rabbit+anti-+GPR126+Polyclonal+Antibody/pm37154297-371-12-14
    Average 91 stars, based on 1 article reviews
    adgrg6 - by Bioz Stars, 2026-09
    91/100 stars
      Buy from Supplier

    Image Search Results


    Expression levels of ADGRG6 mRNA in PAAD and clinical subgroups (GEPIA and UALCAN). ( A ) Comparison of ADGRG6 mRNA expression between PAAD tissues ( n = 179) and normal tissues ( n = 171) from the GEPIA database (TCGA + GTEx). ( B – I ) UALCAN-based subgroup analysis of ADGRG6 expression levels in PAAD samples stratified by sex ( B ), pancreatitis status ( C ), age ( D ), drinking habits ( E ), diabetes status ( F ), tumor grade ( G ), lymph node metastasis ( H ), and TP53 mutation status ( I ). The “normal” group in UALCAN ( n = 4) includes adjacent non-tumor tissues, without subgroup annotations. The comparison to the “normal” group in the UALCAN analysis should be interpreted with caution due to the small size of the normal cohort ( n = 4). “Drinking status” data is incomplete (missing in 80 samples), and comparisons among subgroups should be interpreted cautiously. Subtype descriptions of “Tumor Grade”: Grade 1-Well differentiated (low grade), Grade 2-Moderately differentiated (intermediate grade), Grade 3-Poorly differentiated (high grade), Grade 4-Undifferentiated (high grade). Pathologic descriptions of “Nodal Metastasis Status”: N0-No regional lymph node metastasis, N1-Metastases in 1 to 3 axillary lymph nodes. Data are presented as Mean ± SD. Statistical analysis was performed using Student’s t -test for two-group comparisons and one-way ANOVA followed by Bonferroni’s post hoc test. “*” indicates comparison with the control group; “#” indicates significance between experimental groups (* p < 0.05, ** p < 0.01, *** p < 0.001; # p < 0.05, ## p < 0.01).

    Journal: Current Issues in Molecular Biology

    Article Title: ADGRG6 Promotes Pancreatic Adenocarcinoma Progression Through the NF-κB/STAT6 Axis and Modulation of the Tumor Immune Microenvironment

    doi: 10.3390/cimb47120991

    Figure Lengend Snippet: Expression levels of ADGRG6 mRNA in PAAD and clinical subgroups (GEPIA and UALCAN). ( A ) Comparison of ADGRG6 mRNA expression between PAAD tissues ( n = 179) and normal tissues ( n = 171) from the GEPIA database (TCGA + GTEx). ( B – I ) UALCAN-based subgroup analysis of ADGRG6 expression levels in PAAD samples stratified by sex ( B ), pancreatitis status ( C ), age ( D ), drinking habits ( E ), diabetes status ( F ), tumor grade ( G ), lymph node metastasis ( H ), and TP53 mutation status ( I ). The “normal” group in UALCAN ( n = 4) includes adjacent non-tumor tissues, without subgroup annotations. The comparison to the “normal” group in the UALCAN analysis should be interpreted with caution due to the small size of the normal cohort ( n = 4). “Drinking status” data is incomplete (missing in 80 samples), and comparisons among subgroups should be interpreted cautiously. Subtype descriptions of “Tumor Grade”: Grade 1-Well differentiated (low grade), Grade 2-Moderately differentiated (intermediate grade), Grade 3-Poorly differentiated (high grade), Grade 4-Undifferentiated (high grade). Pathologic descriptions of “Nodal Metastasis Status”: N0-No regional lymph node metastasis, N1-Metastases in 1 to 3 axillary lymph nodes. Data are presented as Mean ± SD. Statistical analysis was performed using Student’s t -test for two-group comparisons and one-way ANOVA followed by Bonferroni’s post hoc test. “*” indicates comparison with the control group; “#” indicates significance between experimental groups (* p < 0.05, ** p < 0.01, *** p < 0.001; # p < 0.05, ## p < 0.01).

    Article Snippet: Sections were then incubated overnight at 4 °C with a rabbit polyclonal anti-ADGRG6 antibody (1:500; Proteintech, Rosemont, IL, USA, Cat. no. 17774-1-AP).

    Techniques: Expressing, Comparison, Mutagenesis, Control

    Protein expression of ADGRG6 in PAAD based on UALCAN and HPA databases. ( A ) Comparison of ADGRG6 protein expression between PAAD tissues ( n = 137) and normal pancreatic tissues ( n = 74) using the UALCAN database (CPTAC dataset). ( B – L ) Subgroup analyses of ADGRG6 protein expression stratified by sex ( B ), chromatin modifier alteration status ( C ), age ( D ), weight ( E ), tumor grade ( F ), tumor stage ( G ), MYC/MYCN alteration ( H ), SWI/SNF complex alteration ( I ), and activity status of the mTOR ( J ), Hippo ( K ), and RTK ( L ) signal pathways. Each subgroup was compared to normal tissues. The “others” group in ( C , H – L ) refers to patients without the specific mutation or alteration listed. ( M ) Representative IHC staining images from the HPA database showing ADGRG6 expression in normal pancreatic tissue and PAAD tissue. Scale Bar: 200 µm. Data are presented as Mean ± SD. Statistical analysis was performed using Student’s t -test for two-group comparisons and one-way ANOVA followed by Bonferroni’s post hoc test. “*” indicates comparison with the control group; “#” indicates significance between experimental groups (* p < 0.05, *** p < 0.001; # p < 0.05).

    Journal: Current Issues in Molecular Biology

    Article Title: ADGRG6 Promotes Pancreatic Adenocarcinoma Progression Through the NF-κB/STAT6 Axis and Modulation of the Tumor Immune Microenvironment

    doi: 10.3390/cimb47120991

    Figure Lengend Snippet: Protein expression of ADGRG6 in PAAD based on UALCAN and HPA databases. ( A ) Comparison of ADGRG6 protein expression between PAAD tissues ( n = 137) and normal pancreatic tissues ( n = 74) using the UALCAN database (CPTAC dataset). ( B – L ) Subgroup analyses of ADGRG6 protein expression stratified by sex ( B ), chromatin modifier alteration status ( C ), age ( D ), weight ( E ), tumor grade ( F ), tumor stage ( G ), MYC/MYCN alteration ( H ), SWI/SNF complex alteration ( I ), and activity status of the mTOR ( J ), Hippo ( K ), and RTK ( L ) signal pathways. Each subgroup was compared to normal tissues. The “others” group in ( C , H – L ) refers to patients without the specific mutation or alteration listed. ( M ) Representative IHC staining images from the HPA database showing ADGRG6 expression in normal pancreatic tissue and PAAD tissue. Scale Bar: 200 µm. Data are presented as Mean ± SD. Statistical analysis was performed using Student’s t -test for two-group comparisons and one-way ANOVA followed by Bonferroni’s post hoc test. “*” indicates comparison with the control group; “#” indicates significance between experimental groups (* p < 0.05, *** p < 0.001; # p < 0.05).

    Article Snippet: Sections were then incubated overnight at 4 °C with a rabbit polyclonal anti-ADGRG6 antibody (1:500; Proteintech, Rosemont, IL, USA, Cat. no. 17774-1-AP).

    Techniques: Expressing, Comparison, Activity Assay, Mutagenesis, Immunohistochemistry, Control

    Prognostic value of ADGRG6 expression in PAAD. ( A ) Kaplan–Meier survival curves showing OS relative to ADGRG6 expression. ( B – I ) Subgroup OS analyses, including ( B , C ) gender, ( D , E ) stage 1–2, ( F ) T2 (tumor size > 2 cm but ≤4 cm), ( G ) T3 (tumor size > 4 cm), ( H ) N0 (no regional lymph node metastasis), and ( I ) M0 (no distant metastasis).

    Journal: Current Issues in Molecular Biology

    Article Title: ADGRG6 Promotes Pancreatic Adenocarcinoma Progression Through the NF-κB/STAT6 Axis and Modulation of the Tumor Immune Microenvironment

    doi: 10.3390/cimb47120991

    Figure Lengend Snippet: Prognostic value of ADGRG6 expression in PAAD. ( A ) Kaplan–Meier survival curves showing OS relative to ADGRG6 expression. ( B – I ) Subgroup OS analyses, including ( B , C ) gender, ( D , E ) stage 1–2, ( F ) T2 (tumor size > 2 cm but ≤4 cm), ( G ) T3 (tumor size > 4 cm), ( H ) N0 (no regional lymph node metastasis), and ( I ) M0 (no distant metastasis).

    Article Snippet: Sections were then incubated overnight at 4 °C with a rabbit polyclonal anti-ADGRG6 antibody (1:500; Proteintech, Rosemont, IL, USA, Cat. no. 17774-1-AP).

    Techniques: Expressing

    Single-cell analysis of ADGRG6 in the TME. ( A ) TISCH database analysis of ADGRG6 expression across different cell types in the TME. ( B , C ) The distribution of ADGRG6 expression in various immune and stromal cell types in the PAAD_CRA001160 and PAAD_GSE154778 datasets. The left panels ( B , C ) depict the Uniform manifold approximation and projection (UMAP) of single-cell transcriptome data with cell typing (major lineages) in the two datasets. The right panels ( B , C ) show the expression of the ADGRG6 gene in different cell types (major lineages) within the two datasets.

    Journal: Current Issues in Molecular Biology

    Article Title: ADGRG6 Promotes Pancreatic Adenocarcinoma Progression Through the NF-κB/STAT6 Axis and Modulation of the Tumor Immune Microenvironment

    doi: 10.3390/cimb47120991

    Figure Lengend Snippet: Single-cell analysis of ADGRG6 in the TME. ( A ) TISCH database analysis of ADGRG6 expression across different cell types in the TME. ( B , C ) The distribution of ADGRG6 expression in various immune and stromal cell types in the PAAD_CRA001160 and PAAD_GSE154778 datasets. The left panels ( B , C ) depict the Uniform manifold approximation and projection (UMAP) of single-cell transcriptome data with cell typing (major lineages) in the two datasets. The right panels ( B , C ) show the expression of the ADGRG6 gene in different cell types (major lineages) within the two datasets.

    Article Snippet: Sections were then incubated overnight at 4 °C with a rabbit polyclonal anti-ADGRG6 antibody (1:500; Proteintech, Rosemont, IL, USA, Cat. no. 17774-1-AP).

    Techniques: Single-cell Analysis, Expressing

    ADGRG6 silencing suppresses PAAD cell proliferation, migration, and invasion in vitro. ( A ) IHC staining of ADGRG6 in PAAD tissues based on tissue microarray analysis, showing higher expression in advanced TNM stages. Scale Bar: 200 µm. ( B ) ADGRG6 mRNA levels in AsPC-1 and BxPC-3 post si- ADGRG6 . ( C ) Cell proliferation of si- ADGRG6 -transfected AsPC-1 and BxPC-3 measured by CCK-8 assay. ( D ) Wound-healing assay demonstrating reduced migration capacity in si- ADGRG6 -transfected AsPC-1 and BxPC-3 cells. Scale Bar: 50 µm. ( E ) Transwell invasion assays (200×) confirming decreased invasive ability post-knockdown. Scale Bar: 50 µm. ( F ) 3D spheroid culture assays demonstrating impaired spheroid growth in si- ADGRG6 cells, quantified by spheroid diameters across 21 days (4×). Scale Bar: 200 µm. Data are presented as Mean ± SD. Statistical analysis was performed using Student’s t -test for two-group comparisons and one-way ANOVA followed by Bonferroni’s post hoc test. “*” indicates comparison with the control group; “#” indicates significance between experimental groups (** p < 0.01, *** p < 0.001; # p < 0.05).

    Journal: Current Issues in Molecular Biology

    Article Title: ADGRG6 Promotes Pancreatic Adenocarcinoma Progression Through the NF-κB/STAT6 Axis and Modulation of the Tumor Immune Microenvironment

    doi: 10.3390/cimb47120991

    Figure Lengend Snippet: ADGRG6 silencing suppresses PAAD cell proliferation, migration, and invasion in vitro. ( A ) IHC staining of ADGRG6 in PAAD tissues based on tissue microarray analysis, showing higher expression in advanced TNM stages. Scale Bar: 200 µm. ( B ) ADGRG6 mRNA levels in AsPC-1 and BxPC-3 post si- ADGRG6 . ( C ) Cell proliferation of si- ADGRG6 -transfected AsPC-1 and BxPC-3 measured by CCK-8 assay. ( D ) Wound-healing assay demonstrating reduced migration capacity in si- ADGRG6 -transfected AsPC-1 and BxPC-3 cells. Scale Bar: 50 µm. ( E ) Transwell invasion assays (200×) confirming decreased invasive ability post-knockdown. Scale Bar: 50 µm. ( F ) 3D spheroid culture assays demonstrating impaired spheroid growth in si- ADGRG6 cells, quantified by spheroid diameters across 21 days (4×). Scale Bar: 200 µm. Data are presented as Mean ± SD. Statistical analysis was performed using Student’s t -test for two-group comparisons and one-way ANOVA followed by Bonferroni’s post hoc test. “*” indicates comparison with the control group; “#” indicates significance between experimental groups (** p < 0.01, *** p < 0.001; # p < 0.05).

    Article Snippet: Sections were then incubated overnight at 4 °C with a rabbit polyclonal anti-ADGRG6 antibody (1:500; Proteintech, Rosemont, IL, USA, Cat. no. 17774-1-AP).

    Techniques: Migration, In Vitro, Immunohistochemistry, Microarray, Expressing, Transfection, CCK-8 Assay, Wound Healing Assay, Knockdown, Comparison, Control

    In vivo evidence of ADGRG6 oncogenic function in zebrafish and murine xenograft models. ( A ) Representative fluorescence microscopy images of zebrafish xenografts injected with CM-DiI-labeled AsPC-1 cells (si-NC vs. si- ADGRG6 ) at 48 h post-injection (hpi), showing reduced tumor fluorescence area in si- ADGRG6 xenografts. Scale Bar: 300 µm. ( B ) Migration distance of tumor cells in zebrafish xenografts at 24 hpi, significantly reduced upon ADGRG6 knockdown. Fluorescence (red) resulting from CM-Dil labeling was used to monitor the behavior of the cells in the zebrafish model. ( C ) Relative ADGRG6 mRNA and ( D ) protein levels in AsPC-1 cells transfected with siRNA. ( E ) Representative images of mice in vivo tumorigenesis assay. ( F ) Representative images of excised tumors from the tumor-bearing mice. ( G ) Body weight of mice across groups was measured every three days for each mouse and the growth curve was plotted ( n = 6). ( H ) Comparison of the tumor weight ( n = 6). Data are presented as Mean ± SD. Statistical analysis was performed using Student’s t -test for two-group comparisons and one-way ANOVA followed by Bonferroni’s post hoc test. * p < 0.05, *** p < 0.001.

    Journal: Current Issues in Molecular Biology

    Article Title: ADGRG6 Promotes Pancreatic Adenocarcinoma Progression Through the NF-κB/STAT6 Axis and Modulation of the Tumor Immune Microenvironment

    doi: 10.3390/cimb47120991

    Figure Lengend Snippet: In vivo evidence of ADGRG6 oncogenic function in zebrafish and murine xenograft models. ( A ) Representative fluorescence microscopy images of zebrafish xenografts injected with CM-DiI-labeled AsPC-1 cells (si-NC vs. si- ADGRG6 ) at 48 h post-injection (hpi), showing reduced tumor fluorescence area in si- ADGRG6 xenografts. Scale Bar: 300 µm. ( B ) Migration distance of tumor cells in zebrafish xenografts at 24 hpi, significantly reduced upon ADGRG6 knockdown. Fluorescence (red) resulting from CM-Dil labeling was used to monitor the behavior of the cells in the zebrafish model. ( C ) Relative ADGRG6 mRNA and ( D ) protein levels in AsPC-1 cells transfected with siRNA. ( E ) Representative images of mice in vivo tumorigenesis assay. ( F ) Representative images of excised tumors from the tumor-bearing mice. ( G ) Body weight of mice across groups was measured every three days for each mouse and the growth curve was plotted ( n = 6). ( H ) Comparison of the tumor weight ( n = 6). Data are presented as Mean ± SD. Statistical analysis was performed using Student’s t -test for two-group comparisons and one-way ANOVA followed by Bonferroni’s post hoc test. * p < 0.05, *** p < 0.001.

    Article Snippet: Sections were then incubated overnight at 4 °C with a rabbit polyclonal anti-ADGRG6 antibody (1:500; Proteintech, Rosemont, IL, USA, Cat. no. 17774-1-AP).

    Techniques: In Vivo, Fluorescence, Microscopy, Injection, Labeling, Migration, Knockdown, Transfection, Comparison

    Regulatory Role of ADGRG6 in the NF-κB→STAT6→GATA3 Signaling Axis. ( A ) KEGG pathway analysis of the gene set co-expressed with ADGRG6 using the LinkInterpreter module; ( B – E ) Pearson correlation analysis between ADGRG6 and key genes of the signaling axis ( NFKB1 , RELA , STAT6 , and GATA3 ) in 178 clinical samples. Values represent Pearson correlation coefficients and corresponding p -values, n = 178; ( F , G ) Relative expression levels of STAT6 and GATA3 genes in the signaling axis in AsPC-1 and BxPC-3 cells after ADGRG6 knockdown detected by RT-qPCR. Data are presented as mean ± standard deviation; ( H , I ) Secretion levels of secretory cytokines IL-6 and IL-8 in AsPC-1 and BxPC-3 cells detected by ELISA; ( J ) Expression and activity of key proteins in the signaling axis after ADGRG6 knockdown detected by Western blot, *** p < 0.001.

    Journal: Current Issues in Molecular Biology

    Article Title: ADGRG6 Promotes Pancreatic Adenocarcinoma Progression Through the NF-κB/STAT6 Axis and Modulation of the Tumor Immune Microenvironment

    doi: 10.3390/cimb47120991

    Figure Lengend Snippet: Regulatory Role of ADGRG6 in the NF-κB→STAT6→GATA3 Signaling Axis. ( A ) KEGG pathway analysis of the gene set co-expressed with ADGRG6 using the LinkInterpreter module; ( B – E ) Pearson correlation analysis between ADGRG6 and key genes of the signaling axis ( NFKB1 , RELA , STAT6 , and GATA3 ) in 178 clinical samples. Values represent Pearson correlation coefficients and corresponding p -values, n = 178; ( F , G ) Relative expression levels of STAT6 and GATA3 genes in the signaling axis in AsPC-1 and BxPC-3 cells after ADGRG6 knockdown detected by RT-qPCR. Data are presented as mean ± standard deviation; ( H , I ) Secretion levels of secretory cytokines IL-6 and IL-8 in AsPC-1 and BxPC-3 cells detected by ELISA; ( J ) Expression and activity of key proteins in the signaling axis after ADGRG6 knockdown detected by Western blot, *** p < 0.001.

    Article Snippet: Sections were then incubated overnight at 4 °C with a rabbit polyclonal anti-ADGRG6 antibody (1:500; Proteintech, Rosemont, IL, USA, Cat. no. 17774-1-AP).

    Techniques: Expressing, Knockdown, Quantitative RT-PCR, Standard Deviation, Enzyme-linked Immunosorbent Assay, Activity Assay, Western Blot